Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical Trial of ONCR-177 at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

On October 1, 2021 Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported it will present initial data from its ongoing Phase 1 clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually (Press release, Oncorus, OCT 1, 2021, View Source [SID1234590640]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ONCR-177, Oncorus’ lead oncolytic Herpes Simplex Virus (oHSV) product candidate, is an intratumorally (iTu) administered viral immunotherapy being developed for multiple solid tumor indications. The Phase 1 open-label, multi-center, dose escalation and expansion clinical trial is designed to evaluate the safety and tolerability of ONCR-177 alone and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with liver metastases of solid tumors.

The details for Oncorus’ SITC (Free SITC Whitepaper) poster are as follows:

Title: Initial results of a Phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors
Abstract #: 511
Primary Author/Presenter: Jong Chul Park, M.D., Instructor, Medicine, Harvard Medical School and Assistant, Medicine, Massachusetts General Hospital
Date/Time: November 12–14, 2021, 7:00 a.m.– 8:30 p.m. ET
Location: Poster Hall, Walter E. Washington Convention Center, Washington, D.C.